Ambroxol in the prevention of acute infections of the upper respiratory tract – a commentary to the study Commentary
Article Sidebar
Published:
Jun 30, 2019
Keywords:
ambroxol, upper respiratory tract infections, infection prophylaxis
Main Article Content
Abstract
Mucolytics are used in both upper respiratory tract infections and chronic respiratory diseases with hypersecretion of airway mucus. It has been proved that they exhibit antioxidative and anti-inflammatory properties. Moreover, it has been observed that ambroxol also has antiviral and immunomodulatory effects. Therefore, its properties could be used in prophylaxis of upper respiratory tract infections. In this commentary we will discuss a study by Nobata et al., which aimed to assess the efficacy of ambroxol in preventing upper respiratory tract infections during a 12-month observation.
Article Details
How to Cite
Mycroft, K., & Górska , K. (2019). Ambroxol in the prevention of acute infections of the upper respiratory tract – a commentary to the study. Medycyna Faktow (J EBM), 12(2(43), 136-139. https://doi.org/10.24292/01.MF.0219.8
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Fendrick A.M., Monto A.S., Nightengale B., Sarnes M.: The Economic Burden of Non-Influenza-Related Viral Respiratory Tract Infection in the United States. Arch. Intern. Med. 2003; 163(4): 487-494.
2. Scaglione F., Petrini O.: Mucoactive Agents in the Therapy of Upper Respiratory Airways Infections: Fair to Describe Them Just as Mucoactive? Clin. Med. Insights Ear Nose Throat. 2019; 12: 1179550618821930.
3. Nobata K., Fujimura M., Ishiura Y. et al.: Ambroxol for the prevention of acute upper respiratory disease. Clin. Exp. Med. 2006; 6(2): 79-83.
4. Moretti M., Fagnani S.: Erdosteine reduces inflammation and time to first exacerbation postdischarge in hospitalized patients with AECOPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2015; 10: 2319-2325.
5. Zeng Z., Yang D., Huang X., Xiao Z.: Effect of carbocisteine on patients with COPD: a systematic review and meta-analysis. Int. J. Chron. Obstruct. Pulmon. Dis. 2017; 12: 2277-2283.
6. Rogers D.F.: Mucoactive Agents for Airway Mucus Hypersecretory Diseases. Respir Care. 2007; 52(9): 1176-1193; discussion 1193-1197.
7. Yang B., Yao D.F., Ohuchi M. et al.: Ambroxol suppresses influenza-virus proliferation in the mouse airway by increasing antiviral factor levels. Eur. Respir. J. 2002; 19(5): 952-958.
8. Han S., Mallampalli R.K.: The Role of Surfactant in Lung Disease and Host Defense against Pulmonary Infections. Ann. Am. Thorac. Soc. 2015; 12(5): 765-774.
9. Takeda K., Miyahara N., Matsubara S. et al.: Immunomodulatory Effects of Ambroxol on Airway Hyperresponsiveness and Inflammation. Immune Netw. 2016; 16(3): 165-175.
10. O’Byrne P.M., Inman M.D., Adelroth E.: Reassessing the Th2 cytokine basis of asthma. Trends Pharmacol. Sci. 2004; 25: 244-248.
11. Ognik K., Cholewińska E.: Biomarkery wykorzystywane w ocenie oksydacyjnych uszkodzeń białek. Kosmos 2018; 2: 347-359.
12. Cazan D., Klimek L., Sperl A. et al.: Safety of ambroxol in the treatment of airway diseases in adult patients. Expert Opin. Drug Saf. 2018; 17(12): 1211-1224.
13. European Medicines Agency (EMA): Środki wykrztuśne ambroksol i bromoheksyna: aktualizacja informacji dotyczących bezpieczeństwa. Opublikowano 14 stycznia 2016 r.
2. Scaglione F., Petrini O.: Mucoactive Agents in the Therapy of Upper Respiratory Airways Infections: Fair to Describe Them Just as Mucoactive? Clin. Med. Insights Ear Nose Throat. 2019; 12: 1179550618821930.
3. Nobata K., Fujimura M., Ishiura Y. et al.: Ambroxol for the prevention of acute upper respiratory disease. Clin. Exp. Med. 2006; 6(2): 79-83.
4. Moretti M., Fagnani S.: Erdosteine reduces inflammation and time to first exacerbation postdischarge in hospitalized patients with AECOPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2015; 10: 2319-2325.
5. Zeng Z., Yang D., Huang X., Xiao Z.: Effect of carbocisteine on patients with COPD: a systematic review and meta-analysis. Int. J. Chron. Obstruct. Pulmon. Dis. 2017; 12: 2277-2283.
6. Rogers D.F.: Mucoactive Agents for Airway Mucus Hypersecretory Diseases. Respir Care. 2007; 52(9): 1176-1193; discussion 1193-1197.
7. Yang B., Yao D.F., Ohuchi M. et al.: Ambroxol suppresses influenza-virus proliferation in the mouse airway by increasing antiviral factor levels. Eur. Respir. J. 2002; 19(5): 952-958.
8. Han S., Mallampalli R.K.: The Role of Surfactant in Lung Disease and Host Defense against Pulmonary Infections. Ann. Am. Thorac. Soc. 2015; 12(5): 765-774.
9. Takeda K., Miyahara N., Matsubara S. et al.: Immunomodulatory Effects of Ambroxol on Airway Hyperresponsiveness and Inflammation. Immune Netw. 2016; 16(3): 165-175.
10. O’Byrne P.M., Inman M.D., Adelroth E.: Reassessing the Th2 cytokine basis of asthma. Trends Pharmacol. Sci. 2004; 25: 244-248.
11. Ognik K., Cholewińska E.: Biomarkery wykorzystywane w ocenie oksydacyjnych uszkodzeń białek. Kosmos 2018; 2: 347-359.
12. Cazan D., Klimek L., Sperl A. et al.: Safety of ambroxol in the treatment of airway diseases in adult patients. Expert Opin. Drug Saf. 2018; 17(12): 1211-1224.
13. European Medicines Agency (EMA): Środki wykrztuśne ambroksol i bromoheksyna: aktualizacja informacji dotyczących bezpieczeństwa. Opublikowano 14 stycznia 2016 r.